Cargando…

Can we develop effective combination antiangiogenic therapy for patients with hepatocellular carcinoma?

Antiangiogenic therapy has shown promise in the treatment of patients with hepatocellular carcinoma (HCC). Bevacizumab, sorafenib, and sunitinib showed efficacy in patients with HCC; and sorafenib is approved by the FDA for treatment of this cancer. In practice, the clinical benefit of these agents...

Descripción completa

Detalles Bibliográficos
Autores principales: Wenger, Justin B., Santos, Napoleon, Liu, Yanxia, Dallas, Jennifer, Subbiah, Sukanthini, Hochwald, Steven, Huang, Emina H., Dang, Duyen T., Allegra, Carmen J., Luesch, Hendrik, Dang, Long H.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Milan 2011
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3179415/
https://www.ncbi.nlm.nih.gov/pubmed/21949574
http://dx.doi.org/10.1007/s12156-011-0082-3
_version_ 1782212512903593984
author Wenger, Justin B.
Santos, Napoleon
Liu, Yanxia
Dallas, Jennifer
Subbiah, Sukanthini
Hochwald, Steven
Huang, Emina H.
Dang, Duyen T.
Allegra, Carmen J.
Luesch, Hendrik
Dang, Long H.
author_facet Wenger, Justin B.
Santos, Napoleon
Liu, Yanxia
Dallas, Jennifer
Subbiah, Sukanthini
Hochwald, Steven
Huang, Emina H.
Dang, Duyen T.
Allegra, Carmen J.
Luesch, Hendrik
Dang, Long H.
author_sort Wenger, Justin B.
collection PubMed
description Antiangiogenic therapy has shown promise in the treatment of patients with hepatocellular carcinoma (HCC). Bevacizumab, sorafenib, and sunitinib showed efficacy in patients with HCC; and sorafenib is approved by the FDA for treatment of this cancer. In practice, the clinical benefit of these agents has been heterogeneous; and in patients who do respond, the benefit is modest and/or short-lived. Recent advances in the molecular understanding of tumor angiogenesis along with the rapid development of targeted drug discovery have made it possible to explore novel combination therapy for HCC. We review the clinical trial results, discuss possible molecular mechanisms of resistance, and suggest novel combinations with antiangiogenic therapy.
format Online
Article
Text
id pubmed-3179415
institution National Center for Biotechnology Information
language English
publishDate 2011
publisher Springer Milan
record_format MEDLINE/PubMed
spelling pubmed-31794152011-09-23 Can we develop effective combination antiangiogenic therapy for patients with hepatocellular carcinoma? Wenger, Justin B. Santos, Napoleon Liu, Yanxia Dallas, Jennifer Subbiah, Sukanthini Hochwald, Steven Huang, Emina H. Dang, Duyen T. Allegra, Carmen J. Luesch, Hendrik Dang, Long H. Oncol Rev Review Antiangiogenic therapy has shown promise in the treatment of patients with hepatocellular carcinoma (HCC). Bevacizumab, sorafenib, and sunitinib showed efficacy in patients with HCC; and sorafenib is approved by the FDA for treatment of this cancer. In practice, the clinical benefit of these agents has been heterogeneous; and in patients who do respond, the benefit is modest and/or short-lived. Recent advances in the molecular understanding of tumor angiogenesis along with the rapid development of targeted drug discovery have made it possible to explore novel combination therapy for HCC. We review the clinical trial results, discuss possible molecular mechanisms of resistance, and suggest novel combinations with antiangiogenic therapy. Springer Milan 2011-08-09 /pmc/articles/PMC3179415/ /pubmed/21949574 http://dx.doi.org/10.1007/s12156-011-0082-3 Text en © The Author(s) 2011 https://creativecommons.org/licenses/by-nc/4.0/ This article is distributed under the terms of the Creative Commons Attribution Noncommercial License which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and source are credited.
spellingShingle Review
Wenger, Justin B.
Santos, Napoleon
Liu, Yanxia
Dallas, Jennifer
Subbiah, Sukanthini
Hochwald, Steven
Huang, Emina H.
Dang, Duyen T.
Allegra, Carmen J.
Luesch, Hendrik
Dang, Long H.
Can we develop effective combination antiangiogenic therapy for patients with hepatocellular carcinoma?
title Can we develop effective combination antiangiogenic therapy for patients with hepatocellular carcinoma?
title_full Can we develop effective combination antiangiogenic therapy for patients with hepatocellular carcinoma?
title_fullStr Can we develop effective combination antiangiogenic therapy for patients with hepatocellular carcinoma?
title_full_unstemmed Can we develop effective combination antiangiogenic therapy for patients with hepatocellular carcinoma?
title_short Can we develop effective combination antiangiogenic therapy for patients with hepatocellular carcinoma?
title_sort can we develop effective combination antiangiogenic therapy for patients with hepatocellular carcinoma?
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3179415/
https://www.ncbi.nlm.nih.gov/pubmed/21949574
http://dx.doi.org/10.1007/s12156-011-0082-3
work_keys_str_mv AT wengerjustinb canwedevelopeffectivecombinationantiangiogenictherapyforpatientswithhepatocellularcarcinoma
AT santosnapoleon canwedevelopeffectivecombinationantiangiogenictherapyforpatientswithhepatocellularcarcinoma
AT liuyanxia canwedevelopeffectivecombinationantiangiogenictherapyforpatientswithhepatocellularcarcinoma
AT dallasjennifer canwedevelopeffectivecombinationantiangiogenictherapyforpatientswithhepatocellularcarcinoma
AT subbiahsukanthini canwedevelopeffectivecombinationantiangiogenictherapyforpatientswithhepatocellularcarcinoma
AT hochwaldsteven canwedevelopeffectivecombinationantiangiogenictherapyforpatientswithhepatocellularcarcinoma
AT huangeminah canwedevelopeffectivecombinationantiangiogenictherapyforpatientswithhepatocellularcarcinoma
AT dangduyent canwedevelopeffectivecombinationantiangiogenictherapyforpatientswithhepatocellularcarcinoma
AT allegracarmenj canwedevelopeffectivecombinationantiangiogenictherapyforpatientswithhepatocellularcarcinoma
AT lueschhendrik canwedevelopeffectivecombinationantiangiogenictherapyforpatientswithhepatocellularcarcinoma
AT danglongh canwedevelopeffectivecombinationantiangiogenictherapyforpatientswithhepatocellularcarcinoma